This study is the first to reveal the clinical usefulness of PAD evaluation: specifically, abnormal SPP may have the potential to identify subclinical but substantial PAD and can predict simultaneous kidney involvement, as well as future progression to ESKD, in patients with AAV. The gene discussed is HM13; the disease is peripheral arterial disease.